Literature DB >> 21962337

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

Tamara Intermesoli, Fausto Castagnetti, Simona Soverini, Adelaide Bussini, Orietta Spinelli, Alessandra Gnani, Renato Bassan, Gianantonio Rosti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962337     DOI: 10.1016/j.leukres.2011.09.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  1 in total

1.  Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.

Authors:  Ahmet Emre Eşkazan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.